

HEREDITARY ANGIOEDEMA (HAE) PRESCRIPTION FORM

1 PATIENT INFORMATION

Patient Name: _____
 Primary Phone: _____
 DOB: _____ Gender: _____
 Address: _____

 Allergy: _____
 Patient Weight: _____ Diagnosis: D84.1 Other _____

2 PRESCRIBER INFORMATION

Prescriber's Name: _____
 Contact Person: _____ Phone: _____
 NPI #: _____
 Address: _____

 City, State, Zip: _____
 Phone: _____ Fax: _____

3 CATHETER ACCESS AND FLUSH PROTOCOL

ACCESS TYPE	CATHETER FLUSH ORDERS
Peripheral	0.9% Saline Flush: Dispense: 30 Days Refills: PRN x 1yr Flush line/port with 10mL for patency/SASH protocol.
PORT (Also include Peripheral IV PRN Port Malfunction)	Heparin Flush: Dispense: 30 Days Refills: PRN x 1yr Flush port with _____ mL of Heparin _____ units/mL per SASH protocol.

4 PRESCRIPTION INFORMATION Please check the following:

MEDICATION	DOSE	DIRECTIONS	DAY SUPPLY	# OF VIALS	REFILLS
BERINERT® (C1 Estrate inhibitor [human])	_____ Units (max 20 IU/kg up to 2500 IU)	_____	_____	_____	_____
CINRYZE® (C1 esterase inhibitor [human])	_____ Units (max 10 IU/kg up to 2500 IU)	_____	_____	_____	_____
FIRAZYR® (Icatibant injection)	_____ Units (30 mg prefilled syringe)	_____	_____	_____	_____
HAEGARDA® C1 Esterase Inhibitor Subcutaneous [human] 60u/kg	_____ Units	_____	28 Days	<input type="checkbox"/> 2000 IU #of vials _____ <input type="checkbox"/> 3000 IU #of vials _____	13
RUCONEST® (C1 esterase inhibitor [recombinant])	_____ Units (50 IU/kg max. 4200 units)	_____	_____	_____	_____
TAKHZYRO® (Ilanadelumab-flyo) injection	_____ Units (300 mg)	administer every 2 weeks (bi-weekly) administer once monthly (monthly)	28 Days	4 vials (bi-weekly) 2 vials (monthly)	13

5 PHYSICIAN SIGNATURE (REQUIRED)

X _____ Date of Signature X _____ Date of Signature
 PRODUCT SUBSTITUTION PERMITTED DISPENSE AS WRITTEN

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee.

HEREDITARY ANGIOEDEMA (HAE) PRESCRIPTION FORM

6 TREATMENT REGIMEN *Administer pre-medication 30-60 min prior to drug infusion*

PRE-MEDICATION

- Antipyretic: _____ Qty: 6 month Refills: PRN x 1yr
- Antihistamine: _____ Qty: 6 month Refills: PRN x 1yr
- EMLA (Lidocaine 2.5%/Prilocaine 2.5%) or LMX4 cream (Lidocaine 4%) Qty: 30 Gram Refills: PRN x 1yr Other: _____
Apply 1-2 hours before port access.

7 ADDITIONAL INSTRUCTIONS

SITE OF CARE

- Self/caregiver administration training # visits ordered _____ or competent
- Home Health Nursing

NURSING INSTRUCTIONS

1. Gain IV access prior to mixing
2. Mix _____ according to package insert (main recommendation)
3. Infuse _____ via IV push over _____

IN CASE OF EMERGENCY

1. Stop medication
2. Call doctor
3. Administer emergency med if ordered in box _____

ADMINISTER EMERGENCY MEDS PER PHYSICIAN ORDERS #q.s. for each drug. Refill: PRN x 1 year

For severe anaphylaxis, administer prescribed Epi-Pen® or equivalent.
If severe symptoms persist, may repeat. **(Please select Epi-Pen® dose):**

- Epi-Pen 0.3 mg autoinjector IM (patients >30 kg)
- Epi-Pen Jr. 0.15 mg autoinjector IM (patients <30 kg)

- Diphenhydramine _____ mg IV push over 2-5 minutes for Infusion Reaction
- Corticosteroid (specify drug and dose):
Other: _____

For severe hypersensitive reaction, stop infusion, administer Epi-Pen®/Epi-Pen Jr Autoinjector IM - may repeat in 20 minutes if needed. Call 911.

8 PHYSICIAN SIGNATURE (REQUIRED)

X _____ X _____
 PRODUCT SUBSTITUTION PERMITTED Date of Signature DISPENSE AS WRITTEN Date of Signature

IMPORTANT NOTICE: This facsimile transmission is intended to be delivered only to the named addressee and may contain material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If it is received by anyone other than the named addressee, the recipient should immediately notify the sender at the address and telephone number set forth herein and obtain instructions as to disposal of the transmitted material. In no event should such material be read or retained by anyone other than the named addressee, except by express authority of the sender to the named addressee.